Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Jennifer A. Wargo"'
Autor:
Tina Cascone, Cheuk H. Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy, Hope Feldman, William N. William, Yuanxin Xi, Sreyashi Basu, Jing Jing Sun, Shalini S. Yadav, Frank R. Rojas Alvarez, Younghee Lee, Aditya K. Mishra, Lili Chen, Monika Pradhan, Haiping Guo, Ansam Sinjab, Nicolas Zhou, Marcelo V. Negrao, Xiuning Le, Carl M. Gay, Anne S. Tsao, Lauren Averett Byers, Mehmet Altan, Bonnie S. Glisson, Frank V. Fossella, Yasir Y. Elamin, George Blumenschein, Jianjun Zhang, Ferdinandos Skoulidis, Jia Wu, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Ravi Rajaram, Mara B. Antonoff, Junya Fujimoto, Luisa M. Solis, Edwin R. Parra, Cara Haymaker, Ignacio I. Wistuba, Stephen G. Swisher, Ara A. Vaporciyan, Heather Y. Lin, Jing Wang, Don L. Gibbons, J. Jack Lee, Nadim J. Ajami, Jennifer A. Wargo, James P. Allison, Padmanee Sharma, Humam Kadara, John V. Heymach, Boris Sepesi
Publikováno v:
Nature Medicine. 29:593-604
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant N
Autor:
Elizabeth M. Park, Manoj Chelvanambi, Neal Bhutiani, Guido Kroemer, Laurence Zitvogel, Jennifer A. Wargo
Publikováno v:
Nature Medicine. 28:690-703
Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy. Our understanding of the complex relationship between different host-intrinsic microorganisms
Publikováno v:
Cell
Unprecedented advances have been made in cancer treatment with the use of immune checkpoint blockade (ICB). However, responses are limited to a subset of patients, and immune-related adverse events (irAEs) can be problematic, requiring treatment disc
Autor:
Miles C. Andrews, Junna Oba, Chang-Jiun Wu, Haifeng Zhu, Tatiana Karpinets, Caitlin A. Creasy, Marie-Andrée Forget, Xiaoxing Yu, Xingzhi Song, Xizeng Mao, A. Gordon Robertson, Gabriele Romano, Peng Li, Elizabeth M. Burton, Yiling Lu, Robert Szczepaniak Sloane, Khalida M. Wani, Kunal Rai, Alexander J. Lazar, Lauren E. Haydu, Matias A. Bustos, Jianjun Shen, Yueping Chen, Margaret B. Morgan, Jennifer A. Wargo, Lawrence N. Kwong, Cara L. Haymaker, Elizabeth A. Grimm, Patrick Hwu, Dave S. B. Hoon, Jianhua Zhang, Jeffrey E. Gershenwald, Michael A. Davies, P. Andrew Futreal, Chantale Bernatchez, Scott E. Woodman
Publikováno v:
Nature Communications. 13
Melanoma cells display distinct intrinsic phenotypic states. Here, we seek to characterize the molecular regulation of these states using multi-omic analyses of whole exome, transcriptome, microRNA, long non-coding RNA and DNA methylation data togeth
Autor:
Y. David Seo, Jennifer A. Wargo
Publikováno v:
Cell Reports Medicine. 4:101039
Autor:
Cheuk Hong Leung, Wayne L. Hofstetter, John V. Heymach, Alexandre Reuben, Myrna C.B. Godoy, Ara A. Vaporciyan, Padmanee Sharma, Yasir Elamin, Neda Kalhor, Robert R. Jenq, Junya Fujimoto, Tina Cascone, Anne S. Tsao, William N. William, Charles Lu, Frank E. Mott, Nadim J. Ajami, Don L. Gibbons, Jack A. Roth, David C. Rice, Luisa M. Solis, Hai T. Tran, Brett W. Carter, Lauren Averett Byers, Andrew Futreal, Lorenzo Federico, Annikka Weissferdt, Garrett L. Walsh, Reza J. Mehran, Chantale Bernatchez, George R. Blumenschein, Jennifer A. Wargo, Heather Lin, Cara Haymaker, Xiuning Le, Jonathan M. Kurie, Mehmet Altan, James P. Allison, Stephen G. Swisher, Edwin R. Parra, Boris Sepesi, Hitoshi Dejima, Frank V. Fossella, Jianjun Zhang, Bonnie S. Glisson, Mara B. Antonoff, Abdul Wadud Khan, Apar Pataer, Alejandro Francisco-Cruz, Ignacio I. Wistuba, Humam Kadara, J. Jack Lee, Ferdinandos Skoulidis
Publikováno v:
Nat Med
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 ran
Autor:
Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, Serigne Lo
Publikováno v:
Nature Medicine. 27:301-309
The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRA
Autor:
Paul Lorigan, Rohit Thakur, Miles C. Andrews, Kate Hogan, Piyushkumar A. Mundra, Richard Marais, Martin G. Cook, Kang Zeng, Louis Boon, Antonia Banyard, Nathalie Dhomen, Matthew Smith, Jennifer A. Wargo, Jonathan Greenall, Elena Galvani, Garry Ashton, A. Mandal, Beth A. Helmink, Pablo Garcia-Martinez, Gabriela Gremel, Christopher P. E. Chester, Sara Valpione
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2
Nature Communications
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2
Nature Communications
Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown. Here we show the genetic and phenotypic changes induced by treatme
Autor:
Eiko Hayase, Tomo Hayase, Mohamed A. Jamal, Takahiko Miyama, Chia-Chi Chang, Miriam R. Ortega, Saira S. Ahmed, Jennifer L. Karmouch, Christopher A. Sanchez, Alexandria N. Brown, Rawan K. El-Himri, Ivonne I. Flores, Lauren K. McDaniel, Dung Pham, Taylor Halsey, Annette C. Frenk, Valerie A. Chapa, Brooke E. Heckel, Yimei Jin, Wen-Bin Tsai, Rishika Prasad, Lin Tan, Lucas Veillon, Nadim J. Ajami, Jennifer A. Wargo, Jessica Galloway-Peña, Samuel Shelburne, Roy F. Chemaly, Lauren Davey, Robert W.P. Glowacki, Chen Liu, Gabriela Rondon, Amin M. Alousi, Jeffrey J. Molldrem, Richard E. Champlin, Elizabeth J. Shpall, Raphael H. Valdivia, Eric C. Martens, Philip L. Lorenzi, Robert R. Jenq
Publikováno v:
Cell. 185:3705-3719.e14
The intestinal microbiota is an important modulator of graft-versus-host disease (GVHD), which often complicates allogeneic hematopoietic stem cell transplantation (allo-HSCT). Broad-spectrum antibiotics such as carbapenems increase the risk for inte
Autor:
Catalin Mihalcioiu, Charlotte E. Ariyan, Michael K. Wong, Aurélie Fluckiger, Julie M. Simon, Rossanna C. Pezo, Michael G. White, Padmanee Sharma, Michael A. Postow, Sapna Pradyuman Patel, Adi Diab, Isabella C. Glitza, Elizabeth M. Burton, Whijae Roh, Zachary A. Cooper, Laurence Zitvogel, Maria Paula Roberti, Wen-Jen Hwu, Alexandria P. Cogdill, Miles C. Andrews, Gladys Ferrere, Abdul Wadud Khan, Scott E. Woodman, Robert R. Jenq, Christine N. Spencer, James P. Allison, Lisa Derosa, Curtis Gumbs, Wei Shen Chen, Stephanie S. Watowich, Irina Fernandez Curbelo, Michael A. Davies, Paule Opolon, Connie P.M. Duong, Jennifer A. Wargo, Maryam Tidjani Alou, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Pierre Olivier Gaudreau, Michael T. Tetzlaff, Didier Raoult, Arielle Elkrief, Khalida Wani, Jeffrey E. Gershenwald, Margaret K. Callahan, Sarah B. Johnson, Alexandre Reuben, Joseph F. Petrosino, Latasha Little, Peter A. Prieto, Matthew Lastrapes, Valerio Iebba, Bertrand Routy, Matthew Adamow, Alexander J. Lazar, Jennifer L. McQuade, Nadim J. Ajami, Golnaz Morad, Rodabe N. Amaria, Matthew C. Wong, Erez N. Baruch, Hussein Abdul-Hassan Tawbi, Satoru Yonekura, Li Zhao, Reetakshi Arora, Luis M Vence, Lauren E. Haydu, Luigi Nezi, Patrick Hwu, P. Andrew Futreal, Jianhua Zhang
Publikováno v:
Nature Medicine
Nature Medicine, 2021, 27 (8), pp.1432-1441. ⟨10.1038/s41591-021-01406-6⟩
Nature Medicine, Nature Publishing Group, 2021, 27 (8), pp.1432-1441. ⟨10.1038/s41591-021-01406-6⟩
Nature Medicine, 2021, 27 (8), pp.1432-1441. ⟨10.1038/s41591-021-01406-6⟩
Nature Medicine, Nature Publishing Group, 2021, 27 (8), pp.1432-1441. ⟨10.1038/s41591-021-01406-6⟩
International audience; Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers and me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b68bdb823308a5d01ebdad2aabf30e
https://hal-amu.archives-ouvertes.fr/hal-03333724/file/2f0091ab-846d-4b59-9960-dcea2f6edc58.pdf
https://hal-amu.archives-ouvertes.fr/hal-03333724/file/2f0091ab-846d-4b59-9960-dcea2f6edc58.pdf